 |
Notes to Editors |
 |
About Archimedes Development Limited
Archimedes Development Limited (ADL) is a subsidiary of Archimedes
Pharma, a fast growing pharmaceutical company focused on
meeting the needs of specialist prescribers in Europe.
ADL is focused on partnering with companies which have
compounds which could benefit from its suite of world-class
drug delivery technologies. These comprise two cutting
intra-nasal delivery technologies ChiSys® and PecSys™ as
well TARGIT®, which is designed to deliver drugs to
precise regions of the large intestine. These technologies
are able to optimise the profile of a wide range of drugs
by allowing targeted or controlled release.
ADL’s world-class drug delivery technologies have
been validated in a series of partnerships with pharmaceutical
and biotechnology companies. ADL has a flexible approach
to its partnering activities and can apply its technologies
to both existing and new therapeutic products.
ADL currently has development deals in
place with a range of companies. Archimedes’ transmucosal enhancement
technology ChiSys® is being used by Javelin Pharmaceuticals
for its nasally-delivered morphine product, Rylomine™*
and PecSys™, a novel pectin-based nasal drug delivery
technology designed to maximise the potential of systemically
absorbed drugs by enhancing drug performance and improving
patient acceptance is also being used in other development
deals.
ADL also has a co-development and commercialisation agreement
with Pharmalink AB under which the two parties are developing
a TARGIT® formulation for an anti-inflammatory product
candidate. The TARGIT® technology is also licensed to
Invapharm for specific drug candidates for various indications.
About ChiSys®
ChiSys is Archimedes’ highly effective transmucosal
enhancement technology, able to overcome many of the limitations
of previous intranasal drug delivery systems. Intranasal
drug delivery offers very fast symptom control and through
the use of ChiSys, patients may have a more acceptable, convenient
and effective means of delivering current injectable therapeutics.
ChiSys increases the residence time of drugs on mucosal
surfaces and has been proven to increase nasal bioavailability
of molecules with a wide range of physiochemical properties,
including hydrophilic small molecules, peptides and proteins.
This creates the opportunity for intranasal drug delivery
for many types of drugs. ChiSys is based around chitosan,
a bioadhesive polysaccharide excipient derived from natural
sources.
ChiSys offers the potential to commercialise molecules previously
thought to be clinically unviable by the nasal route in therapy
areas such as pain, acute seizures, migraine, nausea and
vomiting and panic agitation. Additionally, ChiSys has proven
potential for vaccine delivery, with pre-clinical and clinical
studies demonstrating that chitosan is able to enhance the
immune response of nasally administered vaccines, including
influenza and Norovirus.
A number of regulatory filings (IND/CTA)
have been made for products using ChiSys technology and
pre-clinical studies and clinical trials are currently
in progress to develop ChiSys-based formulations in a broad
range of therapeutic applications. ChiSys is the enabling
technology behind Javelin Pharmaceutical’s Rylomine™*,
an intranasal morphine product in development for post-operative
pain, which recently successfully met the primary endpoint
in a Phase III study.
* Rylomine is a trademark of Javelin Pharmaceuticals
About Ploughshare Innovations Ltd
Ploughshare Innovations Ltd (Ploughshare) is wholly owned
by the United Kingdom’s Secretary of State for Defence.
Ploughshare was formed to commercialise Dstl defence technologies
in non-defence markets and there-by deliver value to Dstl,
the MoD and the UK tax payer. Ploughshare has expanded
its portfolio to include wider Dstl IP and is undertaking
similar commercialisation activities for other parts of
the MoD.
www.ploughshareinnovations.com
back |
